AGILE: ' Exciting ' Survival Results for IDH1-mutated AML AGILE: ' Exciting ' Survival Results for IDH1-mutated AML

Older patients not eligible for intensive chemotherapy had higher complete remission rates and longer overall survival when ivosidenib was added onto azacitidine in the AGILE phase 3 trial.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news